Assessment of the economic value of the INTERCEPT blood system in Belgium
Authors:
- 15 February 2006
- journal article
- Published by Wiley in Transfusion Medicine
- Vol. 16 (1) , 17-30
Abstract
Emerging pathogens continue to threaten blood safety, requiring novel safety approaches. INTERCEPT Blood System for platelets (IBSP) inactivates pathogens, aiming at eliminating the risk of transmitting current and emerging pathogens. The objective was to evaluate the incremental cost-effectiveness ratio (ICER) for IBSP in Belgium. A decision model comparing a 'world with IBSP' to a 'world without IBSP' calculates lifetime costs and 'quality adjusted life years' (QALYs) following platelet transfusion in different indications. Disease-specific life expectancy and consequences of transfusion-transmitted infections were obtained from literature. Transfusion safety and costs were obtained from official sources. Hepatitis C virus-like emerging pathogen was simulated. A wide range of ICERs was observed, highly sensitive to the risk of emerging pathogen trans- mission, underlying disease and age. In the most conservative approach, ICER ranged from 3,459,201 Euro/QALY in absence of emerging pathogen to 195,364 Euro/QALY. The mean threshold of emerging infection risk for IBSP dominance (saving money and producing health gains) ranged from 1/1,079 to 1/2,858 transfusions. Considering the high value authorities appear to place on preventing accidental injury, and ICER of recent implementations in transfusion medicine (NAT: up to 2.3 million Euro per lifeyear), IBSP can be considered cost-effective, taking into account the potential risk of emerging pathogens.Keywords
This publication has 38 references indexed in Scilit:
- Cost‐effectiveness of pathogen inactivation for platelet transfusions in the NetherlandsTransfusion Medicine, 2005
- Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United StatesVox Sanguinis, 2004
- HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementationTransfusion, 2003
- HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimenBlood, 2003
- The future use of pathogen‐inactivated platelet concentratesVox Sanguinis, 2003
- Increased risk of chronic hepatitis in children with cancerMedical and Pediatric Oncology, 2002
- Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term resultsBone Marrow Transplantation, 2002
- Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemiaBritish Journal of Haematology, 2002
- Clinical outcome of hepatitis C as a function of mode of transmissionHepatology, 1998
- Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisalHepatology, 1995